Inactive Instrument

Idogen AB (publ)

Equities

IDOGEN

SE0014428561

Biotechnology & Medical Research

Idogen - Q1 2023 – In a tough situation

May 10, 2023 at 07:37 am

Redeye comments on Idogen following the company’s Q1 2023 report. The lack of financing has put the company in a rough spot, and it is working on a solution. However, liquidation seems to be the most likely scenario ahead.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Latest news about Idogen AB (publ)

Certain Shares of Idogen AB are subject to a Lock-Up Agreement Ending on 12-JUL-2023.	11/07/23	CI
Idogen Delisted from Nasdaq First North Growth Market Amid Bankruptcy	10/07/23	MT
Cell Therapy Group Idogen Formally Files for Bankruptcy After Merger Talks Fail	07/07/23	MT
Idogen Mulls Sale of Proprietary Technology Platform Amid Looming Liquidation	30/05/23	MT
Idogen Mulls Sale of Proprietary Technology Platform Amid Looming Liquidation	30/05/23	MT
Idogen AB Reports Earnings Results for the First Quarter Ended March 31, 2023	09/05/23	CI
Idogen Discusses Reverse Takeover with Several Parties	28/04/23	CI
Idogen to Propose Liquidation at June Annual Meeting, Kicks Off Reverse Merger Talks	28/04/23	MT
Sweden's Idogen Warns of Liquidation if Capital Plan Fails; Shares Plunge 35%	19/04/23	MT
Idogen AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	24/02/23	CI
Idogen AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	24/02/23	CI
Idogen AB Reports Earnings Results for the Full Year Ended December 31, 2022	24/02/23	CI
Idogen AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	25/11/22	CI
Idogen AB Appoints Jan Holgersson to Its Board of Directors	21/11/22	CI
Idogen Chair Steps Down, Former Chairman To Take Up Role Again	02/11/22	MT
Idogen AB Announces Board Changes	01/11/22	CI
Sweden's Idogen Bags Last Tranche of EU Grant for Hemophilia Drug Study	17/10/22	MT
Idogen AB Announces First Patient Enters Idogen's Hemophilia Study Under the Ido 8 Program	13/10/22	CI
Idogen AB Sharpens Focus on its IDO 8 Program and Lowers Operating Expenditure	03/10/22	CI
Idogen AB to Commence the Phase I/IIa Clinical Trial of its Drug Candidate in the IDO 8 Program	03/10/22	CI
Idogen AB Announces Board Changes	27/09/22	CI
Idogen Wins Approval For Hemophilia Medication Study At Oslo University Hospital In Norway	21/09/22	MT
Idogen Receives Approval from the Regional Ethics Committee to Conduct Clinical Phase I/IIa Study	21/09/22	CI
Idogen Appoints Christina Herder as Acting CEO	13/09/22	CI
Redeye Updates Their Analysis of Idogen as Company Approaches Clinical Phase	05/09/22	CI

Chart Idogen AB (publ)

Duration

Period

More charts

Company Profile

Idogen AB is a Sweden-based company engaged in the healthcare industry. The Company is a research-driven entity developing a so called Tolerogenic Vaccine, a treatment concept for anti-drug antibodies, autoimmune diseases and transplant rejection. Its treatment is based on the patient's own dendritic cells (a type of white blood cell) and is taken out and reprogrammed in vitro and then given back to the patient. The Company is in pre-clinical phase and owns a platform technology, from which Idogen AB develops treatment for anti-drug antibodies, as well as autoimmune diseases that cannot be cured. In addition, the Company focuses on the transplantation market by reducing the need for immunosuppressive therapy after transplantation.

Sector

Biotechnology & Medical Research

Calendar

28/05/2024 - Q1 2024 Earnings Release (Projected)

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+7.52%	113B
REGENERON PHARMACEUTICALS, INC.	+11.38%	106B
ARGENX SE	+1.46%	22.27B
BIONTECH SE	-12.64%	22.22B
GENMAB A/S	-5.10%	19.43B
WUXI APPTEC CO., LTD.	-37.85%	17.87B
BEIGENE, LTD.	-8.58%	17.24B
NEUROCRINE BIOSCIENCES, INC.	+7.77%	14.29B
SAREPTA THERAPEUTICS, INC.	+37.41%	12.52B

Bio Therapeutic Drugs